Arcus And Gilead Keep TIGIT Dream Alive Despite Trial Shortcomings
Still In The Game After Mixed Phase II Results
Arcus and Gilead’s latest Phase II readout has produced mixed signals, but some analysts are reassured about the potential of domvanalimab and the wider TIGIT field.
